NCI Data Jamboree (Project Abstract Submission): Submission #35

serial: '35'
sid: '188978'
uuid: 114f69d4-b322-46e2-a462-8577ea09e926
uri: /nci/datajamboree/abstractsubmission
created: '1784982988'
completed: '1784983297'
changed: '1784983297'
in_draft: '0'
current_page: ''
remote_addr: 10.208.24.192
uid: '0'
langcode: en
webform_id: nci_data_jamboree_abstracts
entity_type: node
entity_id: '2272'
locked: '0'
sticky: '0'
notes: ''
metatag: meta
data:
  list_of_additional_authors:
    - add_author_letters: ''
      affiliation: HealthPartners
      first_name: Patricia
      last_name: Mabry
    - add_author_letters: ''
      affiliation: HealthPartners
      first_name: Dylan
      last_name: Zylla
    - add_author_letters: ''
      affiliation: 'Worcester Polytechnic Institute'
      first_name: Jinhong
      last_name: Yu
    - add_author_letters: ''
      affiliation: 'Worcester Polytechnic Institute'
      first_name: Zhikai
      last_name: Xue
  category: 'Employing statistical, computational, and informatics tools, algorithms, and methods to integrate or analyze data'
  degree_s_: Ph.D.
  email: xliu14@wpi.edu
  first_name: Xiaozhong
  keywords_abstracts: 'Immune checkpoint inhibitor–associated myocarditis; Cohort-aware AI; Adverse event surveillance; Longitudinal patient monitoring; Clinical informatics'
  last_name: Liu
  middle_initial: ''
  organization: 'Worcester Polytechnic Institute'
  organization_address:
    address: ''
    address_2: ''
    city: Worcester
    country: ''
    postal_code: ''
    state_province: ''
  summary: |-
    Patients receiving immune checkpoint inhibitors spend most of their treatment time outside the clinic, while rare but rapidly progressive toxicities may emerge between scheduled visits. Immune checkpoint inhibitor-associated myocarditis is a compelling proof-of-concept because early symptoms and biomarker changes can be nonspecific, fragmented, and inconsistently sampled. We propose Onco-Guard, a cohort-aware AI system that evaluates each patient against both the patient’s own longitudinal baseline (self-as-reference) and clinically similar patients receiving comparable regimens (cohort-as-reference). The system will organize clinical, molecular, laboratory, symptom, and physiologic information into reviewable longitudinal trajectories and produce an explicit evidence trace, missing-data indicators, and a prioritized list of patients warranting closer clinical review; it will not make autonomous clinical decisions.

    For the Jamboree, we will investigate whether available NCI and dbGaP resources can support rigorous landmark-based evaluation of earlier toxicity signals. Candidate datasets include phs003413 (checkpoint myocarditis), phs003284 (immune-related adverse events after checkpoint blockade in sarcoma), and phs003412 (Lung-MAP S1400I). Before and during the Jamboree, we will assess variable availability, harmonize usable timelines, define myocarditis phenotypes and recognition timepoints with clinical experts, and compare threshold-based, longitudinal, representation-learning, and agent-assisted approaches while masking all post-landmark information. Evaluation will emphasize event counts, lead time, false-positive burden, uncertainty, and limitations caused by rarity and missing data.

    Our team brings expertise in multimodal AI, patient memory, wearable monitoring, clinical translation, and oncology toxicity workflows, supported by an existing Onco-Guard prototype running on simulated cohorts. Clinical collaborators at HealthPartners will guide phenotype definition, workflow relevance, and human-in-the-loop review. We seek cardio-oncology expertise for phenotype adjudication and NCI data-commons expertise for timeline harmonization. The Jamboree deliverables will be a reusable longitudinal schema, an honest data-readiness and gap analysis, a landmark evaluation pipeline, and a clinically reviewable demonstration that will inform a planned ITCR U01 application.
  title: Professor
  ttile: 'Onco-Guard: Cohort-Aware AI for Earlier Detection of Immune Checkpoint Inhibitor–Associated Myocarditis'